Clinical Trial Update: Afatinib in NSCLC With HER2 Mutation [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of afatinib in non-small cell lung cancer patients with HER2 mutations. The study has completed, and results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2019-10-01